06/23/2026
Last week, Gilead Sciences announced that the U.S. Food and Drug Administration had accepted their application for a once-weekly oral version of lenacapavir, sold as Yeztugo, for HIV prevention. 🔬
A weekly pill would offer yet another alternative, and having more options means more people can find a prevention method that works for them. 💊👩⚕️
The FDA is expected to decide on approval of weekly lenacapavir PrEP pills by February 2, 2027, which could make it the first longer-acting oral PrEP option. 📅